EngeneIC is a biopharmaceutical company focused on developing its proprietary EDV™ nanocell platform for the targeted delivery of chemotherapeutics and functional nucleic acids in cancer. The EDV™ is a first-in-class Cyto-Immunotherapy platform.
Looking for a particular EnGeneIC employee's phone or email?
EnGeneIC Questions
The EnGeneIC annual revenue was $5.2 million in 2026.
Stephen Parker is the Vice President Business Operations of EnGeneIC.
35 people are employed at EnGeneIC.
EnGeneIC is based in North Ryde, New South Wales.
The NAICS codes for EnGeneIC are [541711, 54, 5417, 54171, 541].
The SIC codes for EnGeneIC are [28, 80, 283].
Top EnGeneIC Employees
-
Stephen Parker
Vice President Business Operations at EnGeneIC
Sydney, NSW, AU12 -
Himanshu Brahmbhatt
Joint-CEO and Director at EnGeneIC
Sydney, NSW, AU13 -
11
-
Nancy Mugridge
VP, Alliances at EnGeneIC
Sydney, NSW, AU11 -
Naushad Moti
Research Scientist at EnGeneIC
Sydney, NSW, AU1 -
Ilya Sedliarou
Vice President at EnGeneIC
Sydney, NSW, AU1 -
Reema Gudhka
Research Scientist at EnGeneIC
Sydney, NSW, AU1 -
Henrique Silva
Sr Clinical Research Associate at EnGeneIC
Sydney, NSW, AU2 -
Dhee Biswas
Bioprocess Manufacturing Specialist (Team Leader) at EnGeneIC
Melbourne, VIC, AU3
Related Companies
